116406-19-0

Basic information

• Product Name: trans-3-(2,3,4-Trimethoxyphenyl)-2-propenoic acid
• Synonyms: trans-3-(2,3,4-Trimethoxyphenyl)-2-propenoic acid;(E)-3-(2,3,4-trimethoxyphenyl)acrylic acid;(E)-3-(2,3,4-trimethoxyphenyl)prop-2-enoic acid
• CAS NO: 116406-19-0
• Molecular Formula: C₁₂H₁₄O₅
• Molecular Weight: 238.238
• Mol File: 116406-19-0.mol
• Article Data: 6

Chemical Properties

• Melting Point: 172-173℃
• Boiling Point: 392.2 °C at 760 mmHg
• Flash Point: 149.6 °C
• Appearance: /
• Density: 1.209
• CAS DataBase Reference: trans-3-(2,3,4-Trimethoxyphenyl)-2-propenoic acid(CAS DataBase Reference)
• NIST Chemistry Reference: trans-3-(2,3,4-Trimethoxyphenyl)-2-propenoic acid(116406-19-0)
• EPA Substance Registry System: trans-3-(2,3,4-Trimethoxyphenyl)-2-propenoic acid(116406-19-0)

Safety Data

• Hazardous Substances Data: 116406-19-0(Hazardous Substances Data)

Usage

General Description

Trans-3-(2,3,4-trimethoxyphenyl)-2-propenoic acid, also known as gallic acid, is a naturally occurring organic compound found in various plants, especially in gallnut and sumac. It belongs to the class of polyphenols and is known for its antioxidant properties. Gallic acid has been studied for its potential health benefits, including anti-inflammatory and anti-cancer effects. It is also used in the food and beverage industry as a food additive and flavoring agent. Additionally, gallic acid has been investigated for its potential applications in the pharmaceutical and cosmetic industries due to its various biological activities and potential therapeutic uses.

Upstream product

• 485-90-5 hydrangetin 
• 77-78-1 dimethyl sulfate 
• 634-36-6 1,2,3-trimethoxybenzene 
• 108125-64-0 2,3,4-trimethoxy-trans-cinnamic acid ethyl ester 
• 1530-45-6 (carbethoxymethyl)triphenylphosphonium bromide 
• 2103-57-3 2,3,4-trimethoxybenzaldehyde 
• 141-82-2 malonic acid 
• 882653-77-2 (Z)-3-(2,3,4-trimethoxyphenyl)acrylic acid 

Downstream Products

• 33130-04-0 3-(2,3,4-trimethoxy-phenyl)-propionic acid 
• 1026095-99-7 (E)-N-(6-Amino-2,4-dioxo-1,3-dipropyl-1,2,3,4-tetrahydro-pyrimidin-5-yl)-3-(2,3,4-trimethoxy-phenyl)-acrylamide 
• 69813-30-5 2,6-Bis(2,3,4-trimethoxyphenyl)-3,7-dioxabicyclo<3.3.0>octane-4,8-dione 
• 63234-55-9 3-(2,3,4-trimethoxy-phenyl)-acryloyl chloride 
• 812676-99-6 2-(E-2-bromo-1-ethenyl)-2,3,4-trimethoxybenzene 
• 13058-13-4 (2E)-3-(2,3,4-trihydroxyphenyl)prop-2-enoate 
• 16718-42-6 4,5,6-trimethoxy-1-indanone 

Relevant articles and documents

The First Total Synthesis of Racemic Chebulic Acid

The first total synthesis of racemic chebulic acid is reported, which is the aglycon of several antioxidant ingredients of the fruit of the Terminalia chebula tree. The route started with the straightforward preparation of an indanone-based β-oxoester fro

TUBULIN BINDING AGENTS

The invention provides combretastatin A-4 like compounds that are modified to have enhanced tubulin binding activity and in some embodiments the ability to promote accumulation in the vasculature undergoing angiogenesis (homing activity). The compounds are based on the combretastatin A-4 skeletal structure having a tubulin-binding pharmacophore comprising two fused rings (A and B rings) in which the B ring is substituted with (a) an aromatic ring structure (C ring) and (b) a second substituent/functional group that comes off the B ring. The aromatic ring structure is typically a six membered ring phenolic or aniline structure, or may also be a fused ring structure such as a substituted or unsubstituted naphthalene. The second substituent on the B ring may for example be a substituent which has been found to provide enhanced tubulin binding activity (for example a carbonyl group), or may be a substituent that facilitates functionalisation of the B ring (for example an hydroxyl or amine group), or it may be a binding agent for a target that is preferentially expressed on vasculature undergoing angiogenesis, and not expressed on quiescent vasculature.

Unsymmetrical cyclic diamine compound

A cyclic diamine compound of formula (1): wherein A is (CH2)n, (CH2)n—CH═CH, CO—(CH2)n or CO—(CH2)n—CH═CH, in which n is a number of 0 to 3; Z represents a formula (2) or (3): in which R1, R2, R4, R5 and R6 are individually a hydrogen atom, alkyl group, alkoxy group, halogen atom or nitro group; R3 is a hydrogen atom, alkyl group, alkoxy group, halogen atom, nitro group, naphthyl group, or phenyl group which may be substituted by 1 to 3 substituents selected from the group consisting of alkyl groups, alkoxy groups, halogen atoms, a nitro group and a phenyl group; and X and Y are individually CH or a nitrogen atom; and m is 1 or 2; an acid-addition salt thereof, or a hydrate thereof, and a medicine containing such a compound.